PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its target price upped by research analysts at JPMorgan Chase & Co. from $72.00 to $78.00 in a research report issued to clients and investors on ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $72.

JPMorgan analyst Eric Joseph raised the firm’s price target on PTC Therapeutics (PTCT) to $78 from $72 and keeps an Overweight rating on the ...

Citi analyst Geoff Meacham raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $46 and keeps a Sell rating on the shares ...

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from ...

We feel now is a pretty good time to analyse PTC Therapeutics, Inc.'s (NASDAQ:PTCT) business as it appears the company may be on the cusp of a considerable accomplishment. PTC Therapeutics, Inc., a ...

Learn more about whether Exact Sciences Corporation or PTC Therapeutics, Inc. is a better investment based on AAII's A+ ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a ...

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Underperform to Neutral. As of March 5, 2025, the average one-year price ...